Custom RNA vaccine aims to supercharge cancer immunotherapy

NCT ID NCT05264974

Recruiting now Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 7 times

Summary

This early-phase trial tests a personalized RNA nanoparticle vaccine made from a patient's own tumor. The goal is to help anti-PD-1 immunotherapy work better in people with advanced melanoma or soft tissue sarcoma whose cancer has progressed on standard treatment. Up to 18 participants will receive three doses of the vaccine intravenously, with the main focus on safety and feasibility.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized RNA nanoparticle vaccine made from the patient's own tumor
What this could lead to: If it works, this could make anti-PD-1 immunotherapy more effective for people with advanced melanoma or soft tissue sarcoma.
What could go wrong: This is a very early, small Phase 1 trial focused on safety and feasibility, not yet on effectiveness. The vaccine may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA SOFT TISSUE SARCOMA

Contacts and locations

Locations

University of Florida
RECRUITING

Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.